Oh, so this is why the Feds do everything they can to discourage any investigation into the safety and efficacy of inhaled cannabis.

Medicinal Marijuana Eases Neuropathic Pain in HIV
via The Washington Post

WEDNESDAY, Aug. 6 (HealthDay News) — Medicinal marijuana helps relieve neuropathic pain in people with HIV, says a University of California, San Diego, School of Medicine study.

It included 28 HIV patients with neuropathic pain that wasn’t adequately controlled by opiates or other pain relievers. The researchers found that 46 percent of patients who smoked medicinal marijuana reported clinically meaningful pain relief, compared with 18 percent of those who smoked a placebo.

The study, published online Aug. 6 in Neuropsychopharmacology, was sponsored by the University of California Center for Medical Cannabis Research (CMCR).

“Neuropathy is a chronic and significant problem in HIV patients as there are few existing treatments that offer adequate pain management to sufferers,” study leader Dr. Ronald J. Ellis, an associate professor of neurosciences, said in an UCSD news release. “We found that smoked cannabis was generally well-tolerated and effective when added to the patient’s existing pain medication, resulting in increased pain relief.”

The findings are consistent with and extend other recent CMCR-sponsored research supporting the short-term effectiveness of medicinal marijuana in treating neuropathic pain.

“This study adds to a growing body of evidence that indicates that cannabis is effective, in the short-term at least, in the management of neuropathic pain,” Dr. Igor Grant, a professor of psychiatry and director of the CMCR, said in the UCSD news release.   

By my count, this is the third clinical trial published in just over a year to conclude that inhaling cannabis significantly reduces neuropathic pain. (Read about the others here and here.) And that’s not even including this study that found that low doses of inhaled cannabis are more therapeutic for HIV-positive patients than Marinol (oral synthetic THC).

Kudos to The Washington Post for publicizing this important story. And an extra ’shout out’ to the Post’s editors for highlighting that this trial was sponsored by California’s Center for Medical Cannabis Research and not by the US government.

So if rats can deduce that whole cannabis works better as a medicine than a single synthesized molecule, what’s stopping our federal politicians and bureaucrats from reaching this same conclusion?

Antihyperalgesic effect of a Cannabis sativa extract in a rat model of neuropathic pain: mechanisms involved
via PubMed

This study aimed to give a rationale for the employment of phytocannabinoid formulations to treat neuropathic pain. It was found that a controlled cannabis extract, containing multiple cannabinoids, in a defined ratio, and other non-cannabinoid fractions (terpenes and flavonoids) provided better antinociceptive efficacy than the single cannabinoid given alone, when tested in a rat model of neuropathic pain.

On a separate but related note, am I the only one offended that most scientists appear to be more inclined to document pot’s healing powers in rats and mice than in, say, human beings?

Of course, if you want to enroll in clinical trials intent on documenting so-called “marijuana abuse,” you can take your pick here.

A funny thing happens when the US government begrudgingly allows for double-blind, placebo-controlled clinical trials evaluating the therapeutic efficacy of inhaled cannabis.  

Investigators discover time after time that it works! 

Here are the results from the latest study, conducted at California’s Center for Medical Cannabis Research.   

Low-dose pot eases pain while keeping mind clear
via Reuters News Wire

NEW YORK (Reuters Health) — Giving carefully calibrated doses of smoked marijuana to people with neuropathic pain, which can be difficult-to-treat and extremely painful, can ease their pain without clouding their minds, California researchers report.

Read the full story here. 

Unfortunately, according to recently released legal filings, fewer than 20 investigators in the United States currently possess federal approval to conduct legal clinical research on whole smoked cannabis. (Not surprisingly, most of these researchers are conducting trials that seek to assess the potential physical and mental harms allegedly associated with the drug.) In addition, state funding for the CMCR — which has backed virtually all of the medical cannabis research conducted over the past several years — has dried up and no new appropriations are likely.

Of course, federal officials could readily step in with grant money to keep this important clinical research going — after all, just last month the US National Institute on Drug Abuse announced that it would be spending millions to establish the first-ever ‘Center on Cannabis Addiction‘ — but, needless to say, I’m not holding my breath.